Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial

Triple-negative breast cancer (TNBC) is a highly heterogeneous disease, and molecular subtyping may result in improved diagnostic precision and targeted therapies. Our previous study classified TNBCs into four subtypes with putative therapeutic targets. Here, we conducted the FUTURE trial (ClinicalT...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yi-Zhou, Liu, Yin, Xiao, Yi, Hu, Xin, Jiang, Lin, Zuo, Wen-Jia, Ma, Ding, Ding, Jiahan, Zhu, Xiaoyu, Zou, Jianjun, Verschraegen, Claire, Stover, Daniel G., Kaklamani, Virginia, Wang, Zhong-Hua, Shao, Zhi-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027015/
https://www.ncbi.nlm.nih.gov/pubmed/32719455
http://dx.doi.org/10.1038/s41422-020-0375-9

Ejemplares similares

Ejemplares similares